All stock lists
Inhibitor Therapeutics, Inc. (INTI)
United States · Delayed Price · Currency is USD
Healthcare · Biotechnology
0.10+0.01 (+12.36%)
Market cap
$17.5M
Website
Insider Score
––Not scored
INTI Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
INTI Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| SG&A Expense | 395.03 K | 355.07 K | 557.87 K | 363.43 K | 370.15 K | — |
| R&D Expense | 223.56 K | 340.56 K | 757.25 K | 377.79 K | 325.62 K | — |
| Operating Expenses | 618.60 K | 695.63 K | 1.32 M | 741.22 K | 695.77 K | — |
| Operating Income | -618.60 K | -695.63 K | -1.32 M | -741.22 K | -695.77 K | — |
| Pretax Income | -613.93 K | -686.42 K | -1.30 M | -712.18 K | -659.94 K | — |
| Tax Provision | — | — | — | — | — | — |
| Net Income | -613.93 K | -686.42 K | -1.30 M | -712.18 K | -659.94 K | — |
| EPS (Basic) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| EPS (Diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Shares Outstanding | 173.31 M | 172.57 M | — | 172.57 M | 172.57 M | 172.32 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.